戻る
Apogee Therapeutics Inc (APGE)価格
APGE 株価推移チャート
APGE 収入
Apogee Therapeutics Inc
$69.12
-2.77%
$-1.96
本日現在の状況：Mar 17, 14:36:53 GMT-4
最新の利益結果: Q4 '25
報告済み: 2026-03-02
歴史的収益
四半期
年次
EPS
収入
Earnings FAQ
APGEの最近の1株当たり利益（EPS）は予想と比較してどうでしたか？
Apogee Therapeutics Inc APGEの前四半期の収益はどうでしたか？
Apogee Therapeutics Incの収益見積もりはいくらですか？
Apogee Therapeutics Incの収益品質スコアはどれくらいですか？
Apogee Therapeutics Incはいつ収益を報告しますか？
Apogee Therapeutics Incの予想収益はいくらですか？
Apogee Therapeutics Incは収益予想を上回りましたか？
主要データ
前終値
$71.09
始値
$70.51
当日レンジ
$68.5 - $70.67
52週レンジ
$26.2 - $84.56
取引高
376.6K
平均取引高
974.2K
1株当たり利益(TTM)
-4.22
配当利回り
--
時価総額
$4.7B
APGEとは何ですか？
Apogee Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Waltham, Massachusetts and currently employs 196 full-time employees. The company went IPO on 2023-07-14. The firm is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.